JAMA Internal Medicine
APRIL 6, 2025
This randomized clinical trial compares usual care to an addiction-focused consultation service in hospitalized patients with opioid use disorder.
AuroBlog - Aurous Healthcare Clinical Trials blog
APRIL 6, 2025
Lifesciences industry is at a crossroads. There are numerous opportunities with the transformative AI wave, increased M&A (mergers & acquisition) activity, and digital transformation. However, numerous challenges also lie ahead, said Chandra Ambadipudi, founder and CEO ClairLabs. There are cross-border M&As help companies enter new markets and gain a foothold in emerging economies.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
FDA Law Blog
APRIL 6, 2025
By Andrew J. Hull & David B. Clissold & Sophia R. Gaulkin & Esther Petrikovsky Last week, the Supreme Court issued a unanimous decision in FDA v. Wages & White Lion Investments, LLC , No. 23-1038 (Apr. 2, 2025) that affirms FDAs denial of authorization to market flavored vape products. This opinion, which overrules a Fifth Circuit decision that FDA had acted arbitrarily and capriciously in denying premarket tobacco product applications submitted by manufacturers of flavored e-li
AuroBlog - Aurous Healthcare Clinical Trials blog
APRIL 6, 2025
A necrotic Drosophila wing undergoing regeneration, with NiCP cells in white and the injury in green. (Robin Harris/CC BY 4.0) A new study reveals some surprising discoveries about healing processes that are potentially triggered by the process of necrosis, or premature cell death.
Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
FDA Law Blog
APRIL 6, 2025
Hyman, Phelps & McNamara (HPM) marks its 45thAnniversary year by welcoming three accomplished professionals who reinforce the depth and breadth of the firms FDA and DEA practices. Naomi Lowy joins HPM as a Principal Drug Regulatory Expert after 18 years at the FDAs Center for Drug Evaluation and Research (CDER), most recently as the Deputy Director, Division of General Endocrinology.
Expert insights. Personalized for you.
44 
Let's personalize your content